drug affinity complex is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-01. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
==== MeSH E05.760.833 – tissue preservation ==== MeSH E05.760.833.230 – blood preservation MeSH E05.760.833.445 – cold ischemia MeSH E05.760.833.660 – organ preservation MeSH E05.760.833.890 – semen preservation
==== Interactions with other nephrotoxins ==== Another area of controversy and uncertainty is whether and to what extent vancomycin increases the toxicity of other nephrotoxins. Clinical studies have yielded various results, but animal models indicate that the nephrotoxic effect probably increases when vancomycin is added to nephrotoxins such as aminoglycosides. A dose- or serum level-effect relationship has not been established.
As of this edit, this article uses content from "Anatomy and Physiology", which is licensed in a way that permits reuse under the Creative Commons Attribution-ShareAlike 3.0 Unported License, but not under the GFDL. All relevant terms must be followed.
Sources: en.wikipedia.org
The wound is initially cleaned, debrided and observed, typically 4 or 5 days before closure. The wound is purposely left open. Examples: healing of wounds by use of tissue grafts. If the wound edges are not reapproximated immediately, delayed primary wound healing transpires. This type of healing may be desired in the case of contaminated wounds. By the fourth day, phagocytosis of contaminated tissues is well underway, and the processes of epithelization, collagen deposition, and maturation are occurring. Foreign materials are walled off by macrophages that may metamorphose into epithelioid cells, which are encircled by mononuclear leukocytes, forming granulomas. Usually the wound is closed surgically at this juncture, or the scab is eaten, and if the "cleansing" of the wound is incomplete, chronic inflammation can ensue, resulting in prominent scarring.
Natural nitrogen (7N) consists of two stable isotopes: the vast majority (99.62%) of naturally occurring nitrogen is nitrogen-14, with the remainder (0.38%) being nitrogen-15. Thirteen radioisotopes are also known, with atomic masses ranging from 9 to 23, along with three nuclear isomers. All of these radioisotopes are short-lived, the longest-lived being 13N with a half-life of 9.965 minutes. All of the others have half-lives shorter than ten seconds. Isotopes lighter than the stable ones generally decay to isotopes of carbon, and those heavier beta decay to isotopes of oxygen. Nitrogen-13 is a positron emitter and one of the main isotopes used in medical PET scans.
The Church of Scotland (Lord High Commissioner) Bill is introduced into the House of Commons in order to lift the ban on Roman Catholics becoming the King's representative at the Church of Scotland's annual assembly, after Lady Elish Angiolini KC, a practising Catholic, was appointed to be Lord High Commissioner of the 2025 general assembly. Labour MP Kevin McKenna announces in the House of Commons that he is living with HIV. The UK government publishes a list of 100 proposed locations for potential new towns in England, with Housing Minister Matthew Pennycook saying work on them will begin before the next general election. 14 February – The UK government scraps the role of independent adviser on political violence, created before the last general election. 16 February – Former prime minister Sir John Major warns that the US's isolationist policy could be a threat to world democracy as it could leave a power vacuum and embolden states such as Russia and China. 17 February – Social Democratic and Labour Party leader Claire Hanna announces that the party will decline any invitations to the White House for St Patrick's Day celebrations due to Donald Trump's stance on the Gaza conflict. 19 February – Business Secretary Jonathan Reynolds faces calls for his resignation after he was accused of falsely saying he was a solicitor in his online CV. 20 February – Culture Secretary Lisa Nandy says she will raise concerns with BBC bosses over the documentary Gaza: How To Survive A War Zone, narrated by a 13-year-old boy who is the son of Hamas's deputy minister of agriculture.
===== Divestments ===== On October 21, 2011, Par Pharmaceutical has sealed the deal to three products from Teva Pharmaceutical Industries, which the Israeli firm was required by the US Federal Trade Commission to divest before it could acquire US biotech Cephalon for $6.8 billion. Following the acquisition of Allergan plc generic division some assets have been sold off to meet US antitrust requirements. In June 2016 Indian pharmaceutical company Dr. Reddy's Laboratories Ltd bought 8 (ANDA) Abbreviated New Drug Applications for $350 million in cash. Also in June 2016 Teva sold two ANDAs to Indian pharmaceutical company Zydus Cadilla, strengthening its US portfolio. On June 21, 2016, American pharmaceutical company Amneal Pharmaceutical previously known as Impax Laboratories bought a portfolio of generic drugs from Teva Pharmaceutical Industries for about $586 million. On July 29, Cipla an Indian pharmaceutical company bought three products from Teva. Indian pharmaceutical company, Aurobindo, was in the race to buy some Teva assets. In October 2016, Teva has sold off part of its UK and Ireland generic business to Indian pharmaceutical company Intas Pharma for 600 million pounds (5083 crore Indian rupees) in cash. In August 2016, Australia pharmaceutical company Mayne Pharmaceutical bought a portfolio of drugs from pharmaceutical giant Teva Pharmaceuticals last year for $845 million Australian dollars.
Sources: en.wikipedia.org
== Clinical significance == Human prohibitin 1 has some activity as a virus receptor protein, having been identified as a receptor for Chikungunya Virus (CHIKV) and Dengue Virus 2 (DENV-2). Little else is known about the activity of the prohibitins in viral pathogenesis.
Score 0: There is no need for periodontal treatment. Score 1: Provide patient with Oral hygiene instruction (OHI). Score 2: Provide patient with Oral hygiene instruction (OHI) and remove plaque retentive factors, including all supra- and subgingival calculus and any restoration overhangs. Score 3: Provide patient with Oral hygiene instruction (OHI) and root surface debridement (RSD). Score 4: Provide patient with Oral hygiene instruction (OHI) and root surface debridement (RSD). In addition, patient should be evaluated for the requirement of more complex treatment. A referral to specialists may be needed.
== Factors that affect the specific dynamic action == The specific dynamic action is increased by both aerobic training of sufficient duration and intensity or by anaerobic weight training. Caffeine intake at meals also has been shown to increase TEF by enhancing sympathetic arousal. However, these effects are marginal, amounting to 7-8 calories per hour. The primary determinants of daily TEF are the total caloric content of the meals and the macronutrient composition of the meals ingested. Meal frequency has little to no effect on TEF, assuming total calorie intake for the days are equivalent. Some studies suggest that SDA may be reduced in patients with obesity, especially those with insulin resistance, although research findings are mixed. A low TEF could potentially predispose to obesity by reducing energy expenditure and promoting a positive energy balance. Alternatively, the presence of a low TEF in many patients with obesity may be explained by insulin resistance, which can be related to excess dietary energy and vary in severity with the degree of obesity. Over time, chronic hyperinsulinemia could diminish the ability of cells to respond to insulin, promote adiposity and peripheral insulin resistance, and worsen the risk for type 2 diabetes. Some research shows that TEF may be more severely impaired in patients depending on the grade of insulin resistance, although some other studies have not reproduced that finding.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.